Albert Oriol

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;

Maxim Norkin ;

Jan Staub ;

Catriona Byrne ;

Malin Sydvander ;

Enrique M. Ocio ;

Vincent Ribrag , MD;

Ludk Pour ;

10/22/2019

Subcutaneous (SC) Isatuximab Administration by an On-Body Delivery System (OBDS) in Combination with Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results

Introduction:SC Isa delivery would optimize convenience of administration. Prior results showed SC Isa administered by syringe pump has efficacy and safety comparable to IV Isa; recommend...

Hang Quach ;

Gurdeep Parmar ;

Nobuhiro Tsukada ;

Kazatuka Sunami ;

Albert Oriol ;

Pierre Bories ;

Enrique M. Ocio ;

Chatchada Karanes ;

Sumit Madan ;

Dorothee Semiond ;

Marlene Inchauspe ;

Sandrine Mace ;

Florence Suzan ;

Phillippe Moreau ;

M.H. Prince ;

11/04/2022

Updated Efficacy and Safety of Melflufen in Patients with Relapsed/ Refractory Multiple Myeloma Refractory to Daratumumab and/or Pomalidomide: HORIZON (OP-106)

Purpose of the Study: Despite advances in therapy, MM remains incurable. Patients with late-stage relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or daratumumab...

Hani Hassoun ;

Adrian Alegre ;

Christopher Maisel ;

Amitabha Mazumder ;

Jeffrey A. Zonder ;

Noemi Puig ;

John Harran ;

Sara Thuresson ;

Hanan Zubair ;

Albert Oriol ;

Agne Paner , MD;

Maxim Norkin ;